The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL

BACKGROUND: Dyslipidaemia is a major contributor to the increased risk of cardiovascular disease (CVD) associated with type 2 diabetes (T2D). This study aimed to characterize the extent of lipid-lowering therapy use and its impact on lipid and glycaemic outcomes in people with T2D uncontrolled on or...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanefeld, Markolf, Traylor, Louise, Gao, Ling, Landgraf, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438574/
https://www.ncbi.nlm.nih.gov/pubmed/28526014
http://dx.doi.org/10.1186/s12933-017-0548-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438574/
https://www.ncbi.nlm.nih.gov/pubmed/28526014
http://dx.doi.org/10.1186/s12933-017-0548-0

Ejemplares similares